Actavis 10-K2011 FY Annual report

Filed: 16 Feb 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ABEE, ACA, AI, Alet, Amethia, amethiatm, AmethystTM, Amgen, Anonyme, ANRREW, Anthony, antibody, ANVISA, Appendix, Arcolab, ARTG, Article, Ascent, Atlantic, auditor, Australian, bleeding, blockage, Branch, British, CA, choice, Civ, comment, compromise, compromised, concurrent, conditionally, consecutive, consummated, counterclaim, Coventry, DEF, denial, designee, digital, digitally, distinct, dosing, draft, EDCV, ellaTM, EMA, emphasizing, escalating, Esmya, esomeprazole, EU, Eurocurrency, famciclovir, ferric, forward, Fosamax, FraternalOrder, Friar, GeneressTM, gluconate, GMP, Greece, Greek, grid, highest, incomplete, incurrence, injured, Interbank, Interpace, intrusion, licensor, London, Lybrel, MAA, medicinal, Memorandum, Merck, ministry, misclassified, morale, morphine, multiplied, Nacional, Nexium, NHSA, NOC, Olive, oncology, oppose, organizational, overcome, owner, Paomar, Parkway, Parsippany, pathway, PBS, pharmacovigilence, Pharmahealth, physical, Portuguese, premise, prime, province, Pty, purity, quinine, Quiver, Restated, Restatement, retroactive, retrospective, safe, safeguard, Sanitary, Scheme, scientific, Selwyn, Signature, Societe, Southeast, sovereign, space, Specifar, Spirit, springing, stipulation, stroke, sublimit, Surveillance, swingline, tablet, tampering, TGA, theft, theLeGrand, tightened, tort, TPD, transmission, Tuck, unadjusted, Union, unlicensed, unused, Varvara, Vestura, Vesturatmproduct, wide, Willow, Zarah

Removed: ActionNo, animal, assumption, automatically, biological, blood, Bonnie, borrower, Brewster, Carmichael, CaseNo, chemistry, China, Circle, CivilNo, Clare, closest, compare, declined, demonstrate, dispersed, divest, divested, dronabinol, efficiency, excretion, exercising, explore, extraordinary, Eyetech, fifty, Frameworkissued, geographically, GlaxoSmithKline, guaranteed, healthy, IND, laboratory, Mattersin, metabolism, mg, minimize, modafinil, modified, nonrecurring, omeprazole, onForm, optimal, outlined, payroll, Pharmacia, prepayment, printing, profile, proposing, prostate, Psychology, reportable, Rider, SECRule, shipment, Somerset, tamaction, thisForm, tolerance, unconditional, warrant, Wellbutrin, xl, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Actavis similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. of Section 1350, as Created by Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned officer of Watson Pharmaceuticals, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i) the Annual Report on Form 10-K of the Company for the year ended December 31, 2011 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 15, 2012


By:		/s/ PAUL M. BISARO
		Paul M. Bisaro
		President and Chief Executive Officer (Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.